You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Displaying Drugs List

165 Items
Other Name(s): Zytiga® (Janssen)
Funding:
Exceptional Access Program
  • abiraterone - Metastatic castrate-resistant prostate cancer, with specific criteria
Oct 2016
Other Name(s): Giotrif® (Boehringer Ingelheim)
Funding:
Exceptional Access Program
  • AFAtinib - For first-line monotherapy treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
Aug 2017
Other Name(s): Zaltrap® (Sanofi-aventis)
Apr 2017
Other Name(s): Proleukin® (interleukin-2) (Novartis)
Funding:
New Drug Funding Program
  • Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma
Jan 2017
Other Name(s): Alecensaro™ (Hoffman-La Roche Limited)
Dec 2016
Other Name(s): MabCampath® (Sanofi Genzyme)
Apr 2016
Other Name(s): AMSA P D® (Erfa)
Sep 2011
Other Name(s): Agrylin® (Shire Pharma)
Jul 2017
Other Name(s): Arimidex® (multiple brands available)
Funding:
ODB Limited Use
  • anastrozole - For the treatment of metastatic breast cancer in hormone receptor positive post-menopausal women
  • anastrozole - An alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer
Apr 2016
Other Name(s): Emend®, Emend IV® (Merck)
Funding:
ODB Limited Use
  • aprepitant: In combination with a 5HT3 receptor antagonist and dexamethasone for highly emetogenic chemotherapy (HEC) regimens
  • aprepitant: For patients receiving moderately emetogenic chemotherapy (MEC) regimens AND who have had inadequate symptom control using a 5HT3 antagonist and dexamethasone in a previous cycle.
Sep 2014
Other Name(s): Trisenox® (Lundbeck)
Funding:
New Drug Funding Program
  • Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - First Line Induction of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - Relapsed_Refractory Induction of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
Apr 2016
Aug 2016